Research overview · Updated October 24, 2026
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
This page is a selected, balanced overview of published ingredient research. It includes favorable, mixed, and negative findings. It is not a systematic review, a medical recommendation, or a claim that our finished formulas have been clinically proven. Grouping references under a product identifies ingredients on that product’s label; it does not establish effectiveness of the product.
How to interpret these references
- Preparation matters: root or leaf, fruiting body or mycelium, powder or extract, species, extraction method, and standardization can change the material studied.
- Amounts are not automatically equivalent: an extract’s total weight is different from the amount of its active constituent. A higher milligram number does not establish greater potency or better results.
- Study design matters: small pilots, short trials, surrogate laboratory measurements, and studies in patients have limits when applied to other people or products.
- Look at the whole result: a positive finding on one test does not mean every outcome improved; statistical significance does not necessarily mean a noticeable clinical benefit. Industry funding and study limitations should be reviewed in the source.
- No dosing advice: research amounts are included for comparison only. Do not take extra gummies or combine supplements to imitate a research dose. Follow the bottle’s directions and discuss use with a qualified healthcare professional.
Studies in people with diagnosed conditions are described only to explain the evidence and its limits. They are not recommendations to use our products to diagnose, treat, cure, prevent, or manage those conditions. Neither ingredient research nor a certificate of analysis, by itself, establishes the clinical effectiveness or long-term safety of a finished formula.
BrainRevive: ingredient research and cited works
Label basis: two gummies per serving; ashwagandha 500 mg and 300 mg each of lion’s mane, reishi, shiitake, cordyceps, turkey tail, maitake, and chaga. This is seven mushrooms plus ashwagandha. The label does not specify extract ratios or active-compound standardization. Consult the product label for complete information.
Research on these ingredients did not evaluate BrainRevive gummies. Dose, preparation, and population differences are described below.
Ashwagandha — 500 mg per serving
What was studied: A randomized, double-blind trial enrolled 64 adults experiencing chronic stress. A specific root extract at 300 mg twice daily for 60 days produced favorable stress-questionnaire and cortisol findings versus placebo.
Limits and relevance: This was a small, short trial of an extract standardized to at least 5% withanolides. BrainRevive’s label lists 500 mg ashwagandha without specifying equivalent standardization. The finding is not proof of an effect from this gummy or a basis for treating anxiety or other conditions.
Ashwagandha — additional cognitive research
What was studied: A placebo-controlled pilot in 50 adults with mild cognitive impairment reported favorable results on selected cognitive tests after eight weeks of 300 mg root extract twice daily.
Limits and relevance: The trial involved people with cognitive impairment and a specified preparation. It does not establish benefits in healthy users of BrainRevive, nor a role for the gummies in treating cognitive impairment. Small studies require independent replication.
Lion’s mane — 300 mg per serving
- Docherty and colleagues (2023), Nutrients 15:4842. Acute and chronic lion’s-mane supplementation in healthy young adults.
- Mori and colleagues (2009), Phytotherapy Research 23:367–372. Placebo-controlled lion’s-mane trial in mild cognitive impairment.
- 2025, Frontiers in Nutrition. Acute effects of a standardized lion’s-mane extract on cognition and mood.
What was studied: The 2023 pilot in 41 healthy adults used 1.8 g daily and found faster performance on a specific Stroop task after an acute dose. Its 28-day stress finding was a nonsignificant trend. The small 2009 trial reported cognitive-score benefits during approximately 3 g/day of mushroom tablets in people with mild cognitive impairment.
Limits and relevance: BrainRevive lists 300 mg per serving, substantially less material than in those trials, without demonstrating equivalent preparation. The 2025 crossover trial in 18 healthy adults found no significant overall cognitive or mood benefit after a single 3 g extract dose, despite mixed individual-task results. The literature does not establish a reliable memory benefit from BrainRevive.
Shiitake — 300 mg per serving
What was studied: A four-week dietary study in 52 healthy adults consuming 5 or 10 g of dried shiitake daily reported changes in selected immune-cell activity and other laboratory markers.
Limits and relevance: This was whole-food research at amounts far greater than the labeled 300 mg, with two mushroom-dose groups rather than a mushroom-free placebo group. Immune-marker changes do not show fewer infections or prove that these gummies strengthen immunity.
Turkey tail — 300 mg per serving
What was studied: An open-label randomized study in 24 healthy volunteers examined microbiome changes following a specific turkey-tail-derived polysaccharopeptide preparation, compared with an antibiotic or no treatment.
Limits and relevance: The small trial examined a specialized extracted compound and microbiome composition. It did not establish improved digestive symptoms, and its preparation is not demonstrated to match BrainRevive.
Cordyceps — 300 mg per serving
What was studied: A small placebo-controlled trial tested 4 g/day of a different mushroom blend. An exploratory longer-duration phase suggested benefits on selected exercise measurements.
Limits and relevance: The initial one-week phase did not significantly improve performance versus placebo; only ten volunteers continued the additional two weeks. Results cannot be attributed to cordyceps alone or transferred to BrainRevive’s different blend and amounts.
Reishi — 300 mg per serving
What was studied: Human research exists, but this randomized trial did not support benefits on the studied metabolic and cardiovascular outcomes.
Limits and relevance: We include this negative finding to avoid presenting the research as uniformly favorable. It does not substantiate cardiovascular or disease-treatment claims for BrainRevive.
Maitake — 300 mg per serving
What was studied: A dose-escalation study in 34 postmenopausal breast-cancer survivors examined a specialized polysaccharide extract and found both stimulatory and inhibitory immune measurements.
Limits and relevance: This was not a demonstration of cancer treatment, disease prevention, or an everyday immune benefit. Its specialized population and preparation do not establish benefits from BrainRevive.
Chaga — 300 mg per serving
What was studied: Chaga has laboratory and preclinical research, but the clinical reference notes that safety and efficacy have not been evaluated in clinical studies.
Limits and relevance: We do not present laboratory antioxidant or immune findings as proof of a clinical benefit in people. A clinical reference is distinguished here from a randomized trial.
LifeRevive: ingredient research and cited works
Label basis: two gummies per serving; L-citrulline 1,000 mg; L-arginine 400 mg; CoQ10, resveratrol, ginseng root, ginkgo biloba, rhodiola, quercetin, and forskolin 200 mg each; capsaicin 100 mg. The label does not specify botanical extract ratios or active-compound standardization. L-carnitine is not listed and is not included in this research section.
Research on these ingredients did not evaluate LifeRevive gummies. A matching ingredient name or nominal amount is not proof of matching preparation, absorption, or effect.
CoQ10 — 200 mg per serving
What was studied: Thirteen trials involving 1,126 participants found an overall reduction in fatigue scores versus placebo. CoQ10-only trials used varying doses; the review describes a range of 60–500 mg/day.
Limits and relevance: Populations, formulations, and duration varied. The CoQ10-only subgroup was significant, while the mixed-compound subgroup was not. A labeled 200 mg amount does not establish matching absorption or effects in LifeRevive. These findings do not establish treatment of a fatigue disorder.
L-citrulline — 1,000 mg per serving
What was studied: The meta-analysis found a small pooled benefit on selected high-intensity exercise measures.
Limits and relevance: The pooled effect was small, and individual-study confidence intervals included no effect. Preparations and amounts differed across studies; some research uses citrulline malate, which is not interchangeable by weight with L-citrulline. The result does not demonstrate a stamina or circulation benefit from LifeRevive.
L-arginine — 400 mg per serving
What was studied: A synthesis of randomized clinical trials reported blood-pressure effects under the studied conditions.
Limits and relevance: Blood pressure is a clinical outcome, not a promise of improved exercise or general circulation. Dose, population, and formulation differences prevent assuming an effect from LifeRevive’s 400 mg. This is not a recommendation to treat high blood pressure or substitute supplements for prescribed care.
Resveratrol — 200 mg per serving
- Wong and colleagues (2013). Chronic resveratrol consumption and flow-mediated dilation in obese but otherwise healthy adults.
- Kennedy and colleagues (2010), American Journal of Clinical Nutrition 91:1590–1597. Resveratrol, cerebral blood flow, and cognition.
What was studied: The Wong crossover trial used 75 mg/day trans-resveratrol for six weeks in 28 adults and reported a favorable vascular-function measurement. Kennedy’s acute study examined 250 and 500 mg doses and found cerebral blood-flow changes without corresponding cognitive-performance benefits.
Limits and relevance: A surrogate blood-flow measurement is not evidence of protection against cardiovascular disease or better memory. LifeRevive’s label does not identify an equivalent trans-resveratrol preparation or establish comparable bioavailability.
Ginseng root — 200 mg per serving
What was studied: Ninety subjects received a specified Panax ginseng extract at 1 or 2 g/day, or placebo, for four weeks. Some fatigue outcomes favored supplementation, particularly mental-fatigue measurements.
Limits and relevance: Findings were not uniform across physical-fatigue outcomes. LifeRevive lists ginseng root without identifying the same species, extraction, or ginsenoside standardization, and its labeled amount differs. The trial does not establish improved physical energy from these gummies.
Ginkgo biloba — 200 mg per serving
- Snitz and colleagues (2009), JAMA. Ginkgo biloba and prevention of cognitive decline in older adults.
- DeKosky and colleagues (2008), JAMA. Ginkgo Evaluation of Memory trial: dementia outcomes.
What was studied: The large GEM trial involved 3,069 older adults and did not establish prevention of cognitive decline or dementia.
Limits and relevance: These important negative findings are included for balance. A standardized extract in a long-term trial is not equivalent to unspecified ginkgo material by milligram weight. No dementia-prevention or reliable memory benefit is claimed for LifeRevive.
Rhodiola — 200 mg per serving
What was studied: Some trials reported favorable fatigue findings, but the systematic review found contradictory results and substantial risk-of-bias or reporting concerns.
Limits and relevance: Species, extract standardization, and study quality matter. LifeRevive’s label does not identify equivalence to the preparations studied. This literature does not establish predictable fatigue or performance benefits from the finished product.
Quercetin — 200 mg per serving
What was studied: Eleven studies involving 254 subjects found a statistically significant average endurance-related effect, characterized by the authors as trivial to small.
Limits and relevance: Statistical significance does not guarantee a noticeable benefit. Different amounts, preparations, and participant groups cannot be assumed to match LifeRevive. The finding is not a basis for a large or guaranteed performance claim.
Forskolin — 200 mg per serving
- Godard, Johnson & Richmond (2005), Obesity Research 13:1335–1343. Forskolin consumption and body-composition measurements.
- Henderson and colleagues (2005), Journal of the International Society of Sports Nutrition 2:54–62. Coleus forskohlii extract trial in mildly overweight women.
What was studied: Small studies of standardized Coleus forskohlii extracts produced mixed findings. Godard’s trial reported changes in selected body-composition measures; Henderson’s trial did not demonstrate weight loss versus placebo.
Limits and relevance: These studies used 250 mg of a 10% extract twice daily—50 mg/day of forskolin within 500 mg/day of extract. LifeRevive’s label says “forskolin 200 mg” without an extract percentage. Those quantities must not be treated as equivalent. This page makes no weight-loss, hormone, or metabolic-treatment claim for LifeRevive.
Capsaicin — 100 mg per serving
What was studied: Human studies examined energy expenditure, fat oxidation, appetite, and related measurements, with effects depending on preparation, dose, and study conditions.
Limits and relevance: Capsaicin, capsiate, and other capsinoids differ. Findings on energy expenditure are not proof of meaningful or sustained weight loss, general energy, or endurance. The label does not specify extract standardization, so “100 mg” must not be equated to a studied dose of pure capsaicin or capsinoids. Do not increase intake to reproduce a study.
Safety, interactions, and before-use cautions
Natural does not mean risk-free. Studies reporting tolerability do not establish safety for everyone, for all combinations, or for indefinite use. This page does not replace the bottle’s directions and warnings or individualized advice from a qualified healthcare professional.
- Read all ingredients before use. Avoid a product if you are allergic to an ingredient; mushroom-containing products warrant particular attention for people with mushroom allergies.
- Do not use BrainRevive during pregnancy or breastfeeding because it contains ashwagandha. For either product, obtain professional advice before use if pregnant, breastfeeding, under 18, taking medication, managing a medical condition, or planning surgery.
- Ashwagandha: NIH guidance notes gastrointestinal effects, drowsiness, rare reports of liver injury, and concerns for thyroid or autoimmune disorders and around surgery. Discuss liver or thyroid history and medication interactions with your clinician.
- Ginkgo: NIH guidance notes possible increased bleeding risk with anticoagulants such as warfarin. Have a clinician or pharmacist review blood thinners, antiplatelet medicines, and other supplements before use.
- Forskolin: potential interactions with blood-pressure medicines require review. Laboratory findings do not establish how a particular oral preparation will affect an individual.
- Multi-ingredient supplements can interact with medicines and with each other. Have a pharmacist or clinician review the complete label, particularly if you take medicines affecting blood pressure, blood clotting, blood sugar, thyroid function, sleep, or immune function.
- Stop use and seek medical advice if an adverse reaction occurs. Seek urgent care for severe symptoms or signs of a serious allergic reaction. Keep supplements out of reach of children.
- Do not stop prescribed treatment, delay diagnosis, or use these products as substitutes for medical care, adequate nutrition, sleep, or physical activity.
Safety references: NIH NCCIH: Ashwagandha; NIH NCCIH: Ginkgo; Memorial Sloan Kettering: Forskolin. These organizations do not endorse our products.
Research transparency and regulatory context
Published references are not FDA or FTC approval, certification, or endorsement. There is no disclaimer that turns an unsupported product claim into a supported one. This page does not promise a health result, weight loss, disease prevention, or an alternative to prescribed treatment. An FDA disclaimer does not remove the need for truthful, nonmisleading statements supported by appropriate evidence.
For the applicable principles, see FTC Health Products Compliance Guidance and FDA information on structure/function claims. Journal indexing, researcher affiliation, and the existence of a publication are not endorsements of Powerhouse Vitality.
These references concern individual ingredients or specific preparations studied by researchers. They did not evaluate BrainRevive or LifeRevive gummies. Studied doses, formulations, and participant populations may differ from our products. Findings do not establish that our products produce the same results.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Questions about product information or these references? Email sales@powerhousevitality.com. Powerhouse Vitality is operated by Abundant White Light LLC.